Kesler Norman & Wride LLC Increases Stock Position in Medtronic PLC $MDT

Kesler Norman & Wride LLC increased its position in Medtronic PLC (NYSE:MDT) by 323.4% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 56,831 shares of the medical technology company’s stock after acquiring an additional 43,410 shares during the quarter. Kesler Norman & Wride LLC’s holdings in Medtronic were worth $5,413,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Riverbend Wealth Management LLC grew its holdings in shares of Medtronic by 3.2% during the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock worth $332,000 after purchasing an additional 107 shares in the last quarter. Wynn Capital LLC grew its stake in Medtronic by 2.4% in the 3rd quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock worth $442,000 after buying an additional 110 shares in the last quarter. Meridian Investment Counsel Inc. increased its holdings in shares of Medtronic by 0.4% in the 3rd quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock worth $2,692,000 after buying an additional 110 shares during the last quarter. Saxony Capital Management LLC raised its position in shares of Medtronic by 3.8% during the 3rd quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company’s stock valued at $290,000 after buying an additional 112 shares in the last quarter. Finally, Cape Investment Advisory Inc. lifted its holdings in shares of Medtronic by 3.2% during the 2nd quarter. Cape Investment Advisory Inc. now owns 3,605 shares of the medical technology company’s stock worth $314,000 after acquiring an additional 113 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Trading Down 1.2%

MDT opened at $97.54 on Friday. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The stock has a market cap of $125.04 billion, a PE ratio of 26.29, a PEG ratio of 2.60 and a beta of 0.71. The business has a 50 day moving average of $98.31 and a 200-day moving average of $94.45.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter in the prior year, the company earned $1.26 earnings per share. The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be paid a dividend of $0.71 per share. The ex-dividend date is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s dividend payout ratio (DPR) is presently 76.55%.

Analysts Set New Price Targets

Several research analysts recently issued reports on MDT shares. Royal Bank Of Canada upped their target price on shares of Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. The Goldman Sachs Group set a $111.00 price objective on Medtronic and gave the company a “neutral” rating in a research report on Wednesday, November 19th. Barclays boosted their target price on Medtronic from $111.00 to $116.00 and gave the stock an “overweight” rating in a research report on Thursday. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research note on Monday. Finally, UBS Group lifted their target price on shares of Medtronic from $95.00 to $102.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $110.28.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).